Medicare Enrolled

Dr. Jay Courtright, M.D.

Hematology & Oncology · Dallas, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Consulting-driven
7777 FOREST LN, Dallas, TX 75230
9725667790
In practice since 2006 (19 years)
NPI: 1487692869 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Courtright from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Courtright? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Courtright

Dr. Jay Courtright is a hematology & oncology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Courtright performed 4,151 Medicare services across 1,593 unique beneficiaries.

Between the years covered by Open Payments, Dr. Courtright received a total of $25,468 from 33 pharmaceutical and/or device companies across 90 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Courtright is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 40% volume in TX$ $25,468 industry payments

Medicare Practice Summary

Medicare Utilization ↗
4,151
Medicare services
Top 40% in TX for hematology & oncology
1,593
Unique beneficiaries
$24
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~218 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Comprehensive metabolic blood panel635$10$64
Complete blood count (CBC) with differential547$8$36
Blood draw (venipuncture)482$8$20
Office visit, established patient (30-39 min)365$94$368
Dexamethasone injection (steroid)324$0$1
Office visit, established patient (20-29 min)259$64$250
Injection, granisetron hydrochloride, 100 mcg170$0$24
Lactate dehydrogenase (enzyme) level165$6$31
Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3146$20$128
Ferritin level test (iron stores)108$13$60
Microscopic examination for white blood cells with manual cell count105$4$22
Complete blood count (CBC), automated105$6$34
Iron level test94$6$27
Iron binding capacity test94$9$35
Drug injection, under skin or into muscle78$11$96
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle55$58$211
Hospital follow-up visit, moderate complexity50$61$247
Hospital follow-up visit, low complexity45$38$135
Chest X-ray, 2 views41$17$61
New patient office visit (45-59 min)40$120$565
Administration of chemotherapy into vein, 1 hour or less39$105$707
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less37$23$157
Administration of chemotherapy into vein, each additional hour37$23$161
Hospital follow-up visit, high complexity26$94$357
Injection of additional new drug or substance into vein22$12$108
Red blood count, automated test20$4$23
Injection, diphenhydramine hcl, up to 50 mg20$1$7
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less18$51$313
New patient office visit (30-44 min)12$81$372
Initial hospital admission, moderate complexity12$102$470
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.3% high complexity
17.9% medium
80.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$25,468
Total received (2018-2024)
Avg $3,638/year across 7 years
Top 18% in TX for hematology & oncology
33
Companies
90
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$18,001 (70.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$5,523 (21.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,943 (7.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,905
2023
$12,195
2022
$575
2021
$175
2020
$2,637
2019
$6,469
2018
$511

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$13,844
Blueprint Medicines Corporation
$3,839
Janssen Biotech, Inc.
$3,079
Seattle Genetics, Inc.
$1,592
Janssen Scientific Affairs, LLC
$1,226
CARTER BLOODCARE
$412
Seagen Inc.
$164
Genentech USA, Inc.
$161
AbbVie, Inc.
$148
Pharmacyclics LLC, An AbbVie Company
$124
ADC Therapeutics America, Inc.
$117
Myriad Genetic Laboratories, Inc.
$115
Celgene Corporation
$109
Carter BloodCare
$100
Karyopharm Therapeutics Inc.
$39
Merck Sharp & Dohme Corporation
$38
Daiichi Sankyo Inc.
$35
PFIZER INC.
$32
Gilead Sciences, Inc.
$30
Regeneron Healthcare Solutions, Inc.
$27
Ipsen Biopharmaceuticals, Inc
$24
Amgen Inc.
$24
Lilly USA, LLC
$22
Epizyme, Inc.,
$21
Takeda Pharmaceuticals U.S.A., Inc.
$20
Exelixis Inc.
$20
Novartis Pharmaceuticals Corporation
$18
Heron Therapeutics, Inc.
$17
BeiGene USA, Inc.
$17
Genmab U.S., Inc.
$15
Medtronic USA, Inc.
$14
Verastem, Inc.
$14
MEDIVATION FIELD SOLUTIONS LLC
$11
Top 3 companies account for 81.5% of total payments
Associated products mentioned in payments ›
ADCETRIS · BRUKINSA · CALQUENCE · CINVANTI · Cabometyx · Copiktra · DARZALEX · ERLEADA · Enhertu · Epkinly · IBRANCE · IMBRUVICA · IMFINZI · Imbruvica · KEYTRUDA · KISQALI · KYPHON Balloon Kyphoplasty · LIBTAYO · LUMAKRAS · LUMOXITI · PADCEV · Perjeta · PreciseTumor · RED BLOOD CELLS · SOMATULINE DEPOT · TAZVERIK · TUKYSA · Trodelvy · VENCLEXTA · VERZENIO · Venclexta · XPOVIO · XTANDI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (71%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Equivalent to $614 per 100 Medicare services performed
Looking for a hematology & oncology in Dallas?
Compare hematology & oncologys in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
134
Per 100K population
5.1
County median income
$74,149
Nearest hospital
MEDICAL CITY DALLAS HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Courtright is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (consulting-driven, top 18%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Courtright experienced with comprehensive metabolic blood panel?
Based on Medicare claims data, Dr. Courtright performed 635 comprehensive metabolic blood panel services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Courtright receive payments from pharmaceutical companies?
Yes. Dr. Courtright received a total of $25,468 from 33 companies across 90 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Courtright's costs compare to other hematology & oncologys in Dallas?
Dr. Courtright's average Medicare payment per service is $24. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Courtright) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →